BR0105500A - Process for obtaining colloidal dispersions of amphotericin b; amphotericin b based compositions for enteral, parenteral and topical use; use of these compositions in the treatment of systemic mycoses and parasitic infections - Google Patents

Process for obtaining colloidal dispersions of amphotericin b; amphotericin b based compositions for enteral, parenteral and topical use; use of these compositions in the treatment of systemic mycoses and parasitic infections

Info

Publication number
BR0105500A
BR0105500A BR0105500-3A BR0105500A BR0105500A BR 0105500 A BR0105500 A BR 0105500A BR 0105500 A BR0105500 A BR 0105500A BR 0105500 A BR0105500 A BR 0105500A
Authority
BR
Brazil
Prior art keywords
amphotericin
compositions
enteral
parenteral
treatment
Prior art date
Application number
BR0105500-3A
Other languages
Portuguese (pt)
Inventor
Jose Maciel Junior Rodrigues
Gisele Santos Goncalves
Original Assignee
Univ Minas Gerais
Cristalia Produtos Quimicos E
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minas Gerais, Cristalia Produtos Quimicos E filed Critical Univ Minas Gerais
Priority to BR0105500-3A priority Critical patent/BR0105500A/en
Priority to AU2002347229A priority patent/AU2002347229A1/en
Priority to PCT/BR2002/000157 priority patent/WO2003039435A2/en
Publication of BR0105500A publication Critical patent/BR0105500A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"PROCESSO DE OBTENçãO DE DISPERSõES COLOIDRAIS DE ANFOTERICINA B; COMPOSIçõES à BASE DE ANFOTERICINA B DE USO ENTERAL, PARENTERAL E TóPICO; USO DESTAS COMPOSIçõES NO TRATAMENTO DE MICOSES SISTêMICAS E INFECçõES PARASITáRIAS". A presente invenção tem como objetivo o processo de obtenção de composições contendo a anfotericina B na sua forma superagregada capazes de tratar infecções causadas por fungos, parasitas e outros agentes susceptíveis ao antibiótico supracitado. Trata-se de uma formulação estável da anfotericina B na sua forma superagregada em presença de desoxicolato de sódIo, liofilizada e estéril, reunindo os requisitos para uma formulação injetável de uso enteral, parenteral ou tópico, com toxicidade reduzida se comparada às formas convencionais que veiculam a anfotericina B."PROCESS FOR OBTAINING COLOIDRAY DISPOSITIONS OF AMPHOTHYCIN B; COMPOSITIONS BASED ON AMPHERICIN B FOR ENTERAL, PARENTAL AND TOPIC USE; USE OF THESE COMPOSITIONS IN THE TREATMENT OF SYSTEMIC MICROSES AND PARASITARY INFECTIONS." The present invention is directed to the process of obtaining compositions containing amphotericin B in their superaggregated form capable of treating infections caused by fungi, parasites and other agents susceptible to the above antibiotic. It is a stable formulation of amphotericin B in its superaggregated form in the presence of lyophilized and sterile sodium deoxycholate, meeting the requirements for an injectable formulation for enteral, parenteral or topical use, with reduced toxicity compared to conventional forms that convey amphotericin B.

BR0105500-3A 2001-11-05 2001-11-05 Process for obtaining colloidal dispersions of amphotericin b; amphotericin b based compositions for enteral, parenteral and topical use; use of these compositions in the treatment of systemic mycoses and parasitic infections BR0105500A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
BR0105500-3A BR0105500A (en) 2001-11-05 2001-11-05 Process for obtaining colloidal dispersions of amphotericin b; amphotericin b based compositions for enteral, parenteral and topical use; use of these compositions in the treatment of systemic mycoses and parasitic infections
AU2002347229A AU2002347229A1 (en) 2001-11-05 2002-11-05 Process of obtaining colloidal dispersions of amphotercin b; compounds based on amphothericine b for enteral, paraenteral and topical use; use of these compounds in the treatment of systemic mycoses and parasitic infections
PCT/BR2002/000157 WO2003039435A2 (en) 2001-11-05 2002-11-05 Process of obtaining colloidal dispersions of amphotercin b; compounds based on amphothericine b for enteral, paraenteral and topical use; use of these compounds in the treatment of systemic mycoses and parasitic infections

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR0105500-3A BR0105500A (en) 2001-11-05 2001-11-05 Process for obtaining colloidal dispersions of amphotericin b; amphotericin b based compositions for enteral, parenteral and topical use; use of these compositions in the treatment of systemic mycoses and parasitic infections

Publications (1)

Publication Number Publication Date
BR0105500A true BR0105500A (en) 2004-06-22

Family

ID=3948117

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0105500-3A BR0105500A (en) 2001-11-05 2001-11-05 Process for obtaining colloidal dispersions of amphotericin b; amphotericin b based compositions for enteral, parenteral and topical use; use of these compositions in the treatment of systemic mycoses and parasitic infections

Country Status (3)

Country Link
AU (1) AU2002347229A1 (en)
BR (1) BR0105500A (en)
WO (1) WO2003039435A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0400264D0 (en) * 2004-01-07 2004-02-11 Polytherics Ltd Complexes
CN110343650B (en) * 2019-05-28 2020-12-29 浙江工业大学 Recombinant streptomyces tuberculatus for producing amphotericin B and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity

Also Published As

Publication number Publication date
AU2002347229A1 (en) 2003-05-19
WO2003039435A3 (en) 2004-03-18
WO2003039435A2 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
BRPI0608840B8 (en) pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea, and its preparation process
BR0108734A (en) Acid antimicrobial compositions for treating food and food contact surfaces and methods for using them
BRPI0410503A (en) use of ivermectin for the manufacture of a topical pharmaceutical composition, topical composition and use of the composition
PT1165058E (en) ANTIBIOTICS AZALIDO FOR THE TREATMENT OR PREVENTION TOPICS OF EYE INFECTIONS
BR0110914A (en) Liquid pharmaceutical composition, conjugate, process for the preparation and use of a composition, process for the treatment and prevention of diseases involving anemia, and device for sustained local and systemic release of a composition
BRPI0413318B8 (en) abuse-proof tablet thermally formed without extrusion
ES2100602T3 (en) UNION ELEMENT.
BR0109931A (en) Pharmaceutical Compositions
BR0206636A (en) Composition and antiviral activity of substituted azaindoloxoacetic piperazine derivatives
BR0110922A (en) Displacement of fasteners for manufacturing prefixed and resettable diapers
BR0116922A (en) Process for the manufacture of a low toxicity dimethyl sulfoxide-free parenteral aqueous composition; and low toxicity parenteral aqueous composition free of dimethyl sulfoxide
BR0214184A (en) Compositions containing oils having a specific gravity higher than the specific gravity of water
BR0116431A (en) Macrolide Antibiotics
BR0214901A (en) Use of at least one block copolymer and process to assist in depositing an emulsion on a surface
BR9917365A (en) Process for the treatment of substantially aqueous fluids
TR200401980T4 (en) Tobramycin formulation optimized for aerosol administration
BRPI0510328A (en) ester-linked macrolides useful for the treatment of microbial infections
BRPI0513856A (en) use of a peptide compound
BR9814721A (en) "use of polyols, appropriate device for the treatment or prophylaxis of mucosal infection caused by yeast in mammals, process for therapeutic or prophylactic treatment of mammals suffering from or being subjected to an increased risk of infection of the mucosa caused by yeast, composition for use in this treatment, and, pharmaceutical preparation for use in the prophylactic or therapeutic systemic or topical treatment of mucosal infections caused by yeast. "
BR0215027A (en) 6-Aminomorphinan derivatives, preparation process and its application
BR112014001017A2 (en) use of one or more nucleotides to improve the heat stability of an aqueous micellar casein composition; liquid nutritional composition; a process for heat treating an aqueous micellar casein composition; and method for providing nutrition to a person in need of this
AR027681A1 (en) SUSTAINED RELEASE COMPOSITIONS FOR PARENTERAL ADMINISTRATION
BR0105500A (en) Process for obtaining colloidal dispersions of amphotericin b; amphotericin b based compositions for enteral, parenteral and topical use; use of these compositions in the treatment of systemic mycoses and parasitic infections
BR112022002379A2 (en) Aqueous composition, process for preparing a composition and use of a composition
BR0105296A (en) Conditioning article, use of a conditioning article and manufacturing process

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B08E Application fees: requirement for complementation of annuity fee

Free format text: COMPLEMENTAR A RETRIBUICAO DA 4A,5A,6A,7A,8A,9A,10A,11A ,12A,13A E 14A ANUIDADES DE ACORDO COM A TABELA VIGENTE, REFERENTE AS GUIAS DE RECOLHIMENTO 220400431065,220600339499,220605749997, 220707476817,220806511319,220907711852,221100495228,22 1112898675,221300210308, 221400390332 E 221500297512.

B08G Application fees: restoration
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents)
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)